LivaNova PLC logo
LivaNova PLC LIVN
$ 63.5 -0.45%

Annual report 2025
added 02-25-2026

report update icon

LivaNova PLC Income Statement 2011-2026 | LIVN

Annual Income Statement LivaNova PLC

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

3.81 B 2.28 B 2.95 B 2.59 B 4.43 B 3.22 B 3.3 B 4.29 B 4.1 B 2.31 B 1.83 B - - - -

Shares

54.5 M 54.2 M 53.9 M 53.5 M 50.6 M 48.6 M 48.3 M 48.5 M 48.2 M 48.9 M 32.7 M - - - -

Historical Prices

69.8 42 54.8 48.4 87.4 66.2 75.4 91.5 79.9 45 59.4 - - - -

Net Income

-242 M 63.2 M 17.5 M -86.2 M -136 M -349 M -155 M -189 M -25.1 M -62.8 M 57.8 M 54.9 M 46.4 M 36.1 M 46.7 M

Revenue

1.39 B 1.25 B 1.15 B 1.02 B 1.04 B 934 M 1.08 B 1.11 B 1.01 B 965 M 292 M 282 M 254 M 219 M 190 M

Cost of Revenue

448 M 400 M 398 M 315 M 329 M 339 M 360 M 361 M 353 M 368 M 27.3 M 27.4 M 21.9 M - -

Gross Profit

940 M 853 M 756 M 707 M 706 M 595 M 745 M 734 M 652 M 560 M 264 M 255 M 232 M 199 M 167 M

Operating Income

199 M 129 M -68.5 M -76.8 M -784 K -274 M -172 M -248 M 96.5 M 33.4 M 88.7 M 80 M 78.3 M - -

Interest Expense

664 K 1.1 M 609 K 691 K 50.2 M 40.8 M 15.1 M 9.82 M 7.8 M 10.6 M 21 K 20 K 119 K - -

EBITDA

228 M 154 M -43.8 M -54.4 M 23.8 M -245 M -98.2 M -167 M 210 M 117 M 105 M 93.1 M 83 M 65.7 M 51.9 M

Operating Expenses

- - - - - - 697 M 648 M 523 M 637 M 167 M 167 M 154 M 138 M 118 M

General and Administrative Expenses

549 M 509 M 503 M 469 M 472 M 447 M 507 M 462 M 382 M 357 M - - - - -

All numbers in USD currency

Quarterly Income Statement LivaNova PLC

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

54.6 M 54.6 M 54.4 M 54.3 M 54.4 M 54.2 M 54 M 53.9 M 54 M 53.8 M 53.6 M 53.6 M 53.5 M 53.5 M 53.3 M 53.3 M 51.6 M 48.9 M 48.7 M 48.7 M 48.7 M 48.6 M 48.5 M 48.4 M 48.4 M 48.3 M 48.2 M 48.2 M 48.6 M 48.5 M 48.3 M 48.3 M 48.2 M 48.1 M 48.1 M 48 B 49.1 M 49.1 M 48.9 M 48.9 M 26 M 26 M 26 M - 26.6 M - 26 M - - - 26.7 M - - - - - - - -

Net Income

26.8 M 27.2 M -327 M - 33 M 16.3 M -41.9 M - -7.32 M 1.16 M 7.37 M - -107 M 16.4 M 2.99 M -5.13 M -43.4 M -56.5 M -30.8 M -281 M -14.8 M -89.4 M -88 M -143 M 32.1 M -29.2 M -14.8 M -211 M -7.18 M 15.1 M 13.3 M -112 M 27.8 M 47.5 M 11.3 M -29.8 M -1.57 M 8.96 M -40.4 M -16.9 M -25.1 M -25.1 M 10.5 M 16.5 M 17.3 M 13.5 M 10.5 M - 17.3 M 13.5 M - - - - - - - - -

Revenue

358 M 353 M 317 M - 318 M 319 M 295 M - 286 M 294 M 263 M - 253 M 254 M 240 M 270 M 253 M 264 M 248 M 270 M 240 M 182 M 182 M 288 M 269 M 277 M 251 M 297 M 272 M 287 M 250 M 278 M 251 M 256 M 227 M 250 M 295 M 321 M 287 M 267 M 67.5 M 67.5 M 74.1 M 68.2 M 73.4 M 72 M 74.8 M - 70.1 M 68.9 M - - - - - - - - -

Cost of Revenue

113 M 114 M 96.1 M - 97.1 M 104 M 87.5 M - 84.3 M 88.7 M 89.3 M - 81.7 M 69.8 M 71.7 M - 84.6 M 90.8 M 84.2 M - 92.4 M 65.7 M 142 M - 86.1 M 74.9 M 84.3 M - 94.3 M 92 M 84.6 M - 87.8 M 84 M 80 M - 106 M 131 M 124 M - 9.54 M 9.54 M 7.6 M - 6.77 M - - - - - - - - - - - - - -

Gross Profit

245 M 239 M 221 M - 221 M 215 M 207 M - 202 M 205 M 174 M - 171 M 184 M 168 M 202 M 169 M 172 M 163 M 167 M 148 M 115 M 116 M 205 M 179 M 197 M 164 M 204 M 174 M 194 M 162 M 172 M 162 M 170 M 148 M 125 M 154 M 148 M 132 M 137 M 58 M 58 M 66.5 M 65.5 M 66.7 M 65.6 M 66.5 M - 66.7 M 65.6 M - - - - - - - - -

Operating Income

54 M 54.2 M 48.6 M - 35.6 M 40.2 M 16.2 M - 4.46 M 17.4 M -2.34 M - -132 M 31.8 M 9.5 M 24.8 M 16.4 M -36.3 M -5.7 M -249 M -7.55 M -16.7 M -15.2 M -144 M 25.8 M -29.9 M -20.8 M -276 M -5.76 M 21.6 M 12.5 M 18.9 M 30 M 27.8 M 19.7 M -14.9 M 30.4 M 25 M -9.07 M - -26.4 M -26.4 M 16.7 M - 26.3 M - - - - - - - - - - - - - -

Interest Expense

400 K 200 K -73 K - 275 K 104 K -369 K - 15 M -185 K 13.4 M - 12.7 M 14.4 M 7.84 M - 11.4 M 16.5 M 15.9 M - 14.7 M 5.72 M 10.6 M - 4.77 M 4.05 M 1.66 M - 2.63 M 3.01 M 2.11 M - 1.42 M 1.58 M 2.32 M - 3.5 M 1.98 M 1.19 M - 125 K 22 K 7 K - -7.12 K - - - - - - - - - - - - - -

EBITDA

- - 55 M - - - 22.5 M - - - 3.61 M - -115 M 31.8 M 15.1 M 24.8 M 34.9 M -36.3 M 381 K -249 M 14.7 M -16.7 M -1.64 M -144 M 48.9 M -14.6 M -13.2 M -276 M 19.2 M 38.2 M 20.9 M 18.9 M 57.9 M 45.8 M 28.5 M -14.9 M 52.9 M 43.1 M 14.5 M - -22.8 M -24.9 M 18.7 M - 26.3 M - 2.1 M - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 180 M 172 M 150 M - 132 M 142 M 128 M - 165 M 168 M 199 M - 84.3 M 84.3 M 49.8 M - 40.4 M - - - - - - - - - - - - - -

General and Administrative Expenses

139 M 138 M 134 M - 127 M 125 M 130 M - 135 M 126 M 124 M - 115 M 116 M 119 M - 109 M 123 M 116 M - 104 M 103 M 228 M - 123 M 127 M 126 M - 115 M 123 M 104 M - 97.2 M 94.3 M 87.3 M - 109 M 121 M 116 M - 41.2 M 41.2 M 29.7 M - 29.6 M - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company LivaNova PLC (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 62.59 -0.37 % $ 92.7 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 12.07 0.33 % $ 1.63 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.59 1.2 % $ 36.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Delcath Systems Delcath Systems
DCTH
$ 9.7 0.73 % $ 347 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.45 1.77 % $ 129 M franceFrance
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 81.19 0.17 % $ 47.5 B usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 18.6 0.05 % $ 122 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 4.13 0.49 % $ 874 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 36.74 -0.05 % $ 5.47 K usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
AxoGen AxoGen
AXGN
$ 32.64 -5.23 % $ 1.5 B usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.9 2.15 % $ 1.15 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 9.31 -2.31 % $ 717 M usaUSA
Inogen Inogen
INGN
$ 6.36 2.42 % $ 169 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.0 1.66 % $ 16.9 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 95.66 -0.59 % $ 1.22 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 85.63 -1.4 % $ 2.97 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Align Technology Align Technology
ALGN
$ 171.87 0.74 % $ 12.9 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.94 -0.75 % $ 374 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
LENSAR LENSAR
LNSR
$ 5.89 -2.81 % $ 70.4 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.38 0.11 % $ 266 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.36 2.26 % $ 55.3 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Medtronic PLC Medtronic PLC
MDT
$ 86.28 -0.4 % $ 111 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.88 -1.02 % $ 573 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Myomo Myomo
MYO
$ 0.7 4.84 % $ 29.3 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 11.77 2.08 % $ 466 M curacaoCuracao
PAVmed PAVmed
PAVM
$ 10.04 1.93 % $ 6.73 M usaUSA